Table 2 Clinical outcomes of trastuzumab beyond disease progression
Median follow-up 39.6 months | ||||
|---|---|---|---|---|
Median duration of trastuzumab therapy 16.5 months | ||||
| Â | First-line trastuzumab (n = 57) | Second-line trastuzumab (n = 55) | Third-line trastuzumab (n = 26) | Fourth-line trastuzuamb (n = 12) |
Objective response rate | Â | Â | Â | Â |
   CR + PR, (number) percentage | (20)a 35 | (9)b 16 | (4)c 15 | (0) 0 |
   CR, (number) percentage | (6) 10.5 | (2) 3.5 | (0) 0 | (0) 0 |
   PR, (number) percentage | (14) 24.5 | (7) 12.5 | (4) 15 | (0) 0 |
Clinical benefit, percentage (CR + PR + SD) | 74 (6 + 14 + 22) | 53 (2 + 7 + 20) | 60 (0 + 4 + 11) | 17 (0 + 0 + 2) |
Time to progression in months, median (range) | 7.25 (1.5–46.5) | 5.25 (1.25–34.2) | 5.25 (1–33.5) | 3.75 (1–7) |